140 results about "Chymase" patented technology

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with i PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with i PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.

A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the 10 method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a 13 receptor blocker; an imidazoline receptor antagonist; a centrally acting tx receptor antagonist; a peripherally acting ct receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduce SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.

The invention relates to the field of biological engineering, in particular to an extraction method of trypsin-chymotrypsin. In the invention, CaCl2 is adopted to activate chymotrypsinogen into the trypsin-chymotrypsin, and simultaneously (NH4)2SO4 is added to generate CaSO4 precipitation and adsorb the trypsin-chymotrypsin; the white freeze-dried powder can be obtained directly through the stepsof elution, salting out, ultrafiltration and freeze-drying, with no need of preparing by the following steps: firstly salting out multiple crystallization joint dialysis and an organic solvent methodof alcohol and acetone and the like is adopted to prepare the trypsin-chymotrypsin crude product, and then the complex steps of CM-cellulose column chromatography and affinity chromatography and the like are carried out for purifying preparation. The extraction method in the invention is convenient and feasible, and is applicable to industrial production, thus saving cost and shortening time whichis shortened to 3 to 4 days from the original required 7 to 8 days. 4.0-4.5 grams of freeze-dried trypsin-chymotrypsin powder can be obtained from per kilogram of pancreas, wherein, the specific activity of chymotrypsin is 355 U./mg protein (nitrogen) and the specific activity of trypsin is 1361 U./mg protein (nitrogen).

A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved:

a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.

The invention discloses a trypsin-chymotrypsin electrochemical synchronous detection method based on enzyme digestion and belongs to the technical field of electrochemical sensing. Through gold-mercapto bond action, a DNA-polypeptide compound is fixed to the surface of a gold electrode, and through DNA hybridization reaction, a DNA-gold nanoparticle-electronic mediator nanometer signal probe is captured. When target protease exists, an arginine carboxyl site of one of polypeptides is cut by trypsin and a tyrosine carboxyl site of the other one of the polypeptides is cut by chymotrypsin so that the corresponding nanometer signal probes connected to the polypeptides are separated from the surface of the electrode and thus peak current of the corresponding electronic mediator is reduced. Therefore, the trypsin-chymotrypsin electrochemical synchronous detection method can realize synchronous detection of sensitivity and selectivity of trypsin and chymotrypsin.

The invention discloses a promotor CPIP from Oryza Sativa L in the plant genetic engineering domain, which is characterized by the following: the promotor CPIP possesses SEQ ID NO: 1 with nucleic acid sequence, which controls two alfapsin inhibition sub-genes simultaneously; the alfapsin inhibition sub-gene is controlled by promotor CPIP in backward-forward direction, which makes answering reaction with arid, salt-forced and abscisic acid(ABA); the promotor region contains a plurality of hostile environment answering cis-form appliance elements; the promotor CPIP controls GUS report gene in backward-forward direction to converse rice; the GUS gene is induced and expressed strongly in the condition of arid and salt-forced.

The present invention relates to a b.fragilis signal molecule microbial preparation, the b.fragilis bacterium are inoculated in a culture medium for anaerobic fermentation at 35 to 38 DEG C, after that, the b.fragilis bacteria concentrate is obtained by centrifugal concentration; the bacteria cell walls are broken by high pressure; further, the bacteria concentrate is treated with enzyme hydrolysis by trypsin, chymotrypsin and pepsin, and then the preparation raw powder is obtained by solvent extraction and decompression drying. The preparation raw powder is taken as the main ingredient, and other excipients are added to prepare the oral capsules, tablets, granules, oral liquor and other preparations. The b.fragilis signal molecule product of the present invention is proven to have no acute toxicity, no influence on the times of spontaneous activity, blood pressure and respiration of the animals and can not cause the allergic reactions of the animals by animal trials. The animal trials further prove that: the product has the effects of regulating blood-lipid metabolism, reducing fat accumulation and slimming; at the same time, the present invention can improve the immunity and the anti-tumor effect by adjusting the gene expression and regulating the immune functions.

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R<1 >and R<2 >are the same or different, and denote a lower alkyl group or a phenyl group, or R<1 >and R<2 >are taken together to form a ring, R<3 >denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR<4 >(R<4 >is hydrogen or optionally substituted lower alkyl group), or NB<2>R<5 >(R<5 >is aryl group, and B<2 >is carbonyl group or sulfonyl group), and B<1 >denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

Azlactone Compound (2) is reacted with Amidine Compound (3) to give Pyrimidine Compound (1) which is useful as an intermediate for the production of enzyme inhibitors (e.g., elastase inhibitor, chymase inhibitor etc.):

wherein each symbol is as defined in the specification.

The invention relates to an microcin C7 heptapeptide with an amino acid sequence of MATINAN. The heptapeptide has stronger biological characteristics of heat resistance, pepsin resistance, trypsin resistance and chymotrypsin resistance, high stability and strong bacteriostatic activity. The invention further provides a high-throughput screening method for obtaining a heat-resistant and protease-resistant strain. A lactobacillus johnsonii strain capable of producing the heptapeptide is screened out; the lactobacillus johnsonii strain is deposited in China General Microbiological Culture Collection Center on October 16th, 2019, and has the accession number CGMCC No.18695. The lactobacillus johnsonii strain has advantages of good stress resistance and high secretion amount and is low in cost.An important foundation is laid for industrial large-scale preparation of microcin C7 heptapeptide in the fields of animal husbandry feed, cosmetics, health care products and the like.

The present Invention relates to a novel acetamide derivative represented by the following Formula 1, which has an inhibition activity for chymotrypsin type proteases and is useful as an inhibitor for the above enzyme, especially as an inhibitor for chymase, and the use thereof as a medicine, for example, an antiasthma drug or a drug for curing vascular injuries complicated with angiogenesis and atheroma.wherein R0 represents a substituted or unsubstituted phenyl group, R1 represents an aryl group, a heteroaryl or an aliphatic lower alkyl group with or without substituents, R2 represents a substituted or unsubstituted alkyl, an aryl alkyl, a heteroaryl alkyl, and a heteroaryloxy alkyl or the like, J represents a carbonyl group, or a methylene group or the like, L represents a methoxy, hydroxyl or acetyloxy group or the like, X and Y independently represents a nitrogen atom or a carbon atom, Z represents a methylene group or a polyethylene group optionally having a substituent.

According to this invention, there is provided an indole derivative having the general formula (I) wherein A is an oxygen atom or a nitrogen atom which nitrogen atom is optionally substituted with an alkyl group, and (i) R<1 >and R<2 >each stand for a hydrogen atom or an alkyl group, independently, or (ii) R<1 >and R<2 >as taken together form a cycloalkyl group or an aromatic ring, or (iii) R<1 >and R<2 >as taken together form a heterocyclic ring, and R<3 >is a hydrogen atom, a (C1-C10)alkyl group or others, R<4 >is a substituted alkyl group and R<5 >is a hydrogen atom, a halogen atom, an alkyl group or an alkoxy group and so on, as novel compounds by a novel chemical synthetic process. The indole derivative of formula (I) exhibits a useful chymase inhibitory activity.

The present invention relates to medicinal products, as well as to health and wellness food products, and particularly to a medicinal product or a health and wellness food product for inhibiting Angiotensin Converting Enzyme and Chymase enzyme pathways.

The present invention relates to medicinal products, as well as to health and wellness food products, and particularly to a medicinal product or a health and wellness food product for inhibiting Angiotensin Converting Enzyme and Chymase enzyme pathways.

A method for the preparation of a polypeptide of interest in authentic form by enzymatic cleavage of fusion proteins using Granzyme B protease (EC 3.4.21.79). There is also provided fusion proteins comprising a polypeptide of interest and a fusion partner, wherein the junction region between the polypeptide of interest and the fusion partner comprises a Granzyme B protease cleavage site adjacent to the polypeptide of interest, and a human Granzyme B protease variant wherein the Cystein residue no. 228 (chymotrypsinogen numbering) is mutated to Phenylalanine.

Disclosed are small molecule inhibitors of the formula (I): and the pharmaceutical compositions thereof and processes of making the same. The compounds are useful in treating various diseases and conditions involving chymase.

The present invention provides drugs containing chymase inhibitors as active ingredients for improving glucose intolerance or preventing and/or treating diseases caused by glucose intolerance. The diseases caused by glucose intolerance are diabetes and/or diabetes complications, wherein the diabetes complications include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinism, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, angitis, stroke, hypertension, renal insufficiency, nephropathy, nephritis, renal artery aneurysm, renal infarction, obesity and the like.